Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Affymax brings in $42mm through private placement

Executive Summary

Affymax (treatments for kidney diseases and associated illnesses) grossed $42mm through a private placement led by ProQuest and including existing investors Sprout Group and Bessemer Venture Partners, along with new buyer Biotechnology Value Fund. The company issued a total of 3.5mm common shares at two different prices: 2.84mm shares were sold at $11.25 each (a 28% discount), and 652k common shares were issued at $15.33 each (a discount of 2%), with investors also receiving five-year warrants to purchase an additional 424k shares at $16.78. Proceeds will be used to support Affymax's lead program Hematide, partnered with Takeda for anemia in chronic kidney disease patients.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies